What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Slides:

Advertisements

Similar presentations

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Advertisements

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

Recent Advances in NSCLC Treatment

Patient Case 1 Patient Case 1: PET/CT Scan.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Treatment Algorithms in Melanoma: Past, Present, and Future

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

Advanced NSCLC Without Actionable Mutations

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Progression After Cancer Immunotherapy in Advanced NSCLC

Updates in Lung Cancer: Insights From Vienna

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Optimizing Outcomes in the Management of GIST

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

nAMD: Switching Therapies - what you need to know

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Management of Glioblastoma

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Basics of Immunotherapy Potential Therapeutic Targets.

Treating mRCC After Initial Antiangiogenic Therapy:

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Evolving Concepts in the Management of Head and Neck Cancers

Immune Checkpoint Inhibitors in Lung Cancer

The Road to Quality Improvement in HER2-Positive Breast Cancer

Putting Evidence Into Practice: Highlights From Toronto

Advances in Gastrointestinal Cancers

Patient-Centered Management in BRAF-Positive Metastatic Melanoma

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

The Changing Field of Melanoma: Ipilimumab.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Preparing for Checkpoint Inhibitors in Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

Optimizing Outcomes in Patients With NSCLC and Liver Metastases

Third-Generation EGFR TKIs

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Moving Care Forward in Advanced Gastric Cancer

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Physiologic vs Chronologic Age

Evaluating the Totality of Evidence

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

Physiologic vs Chronologic Age

Recent Developments in the Treatment of Advanced and Metastatic RCC

Updates in Best Practices in Non-Small Cell Lung Cancer

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Treatment Options for EGFR Mutation-Positive NSCLC

Frontline Metastatic Treatment Options in EGFRm NSCLC

TKI + VEGF Inhibition RELAY Trial: Erlotinib +/- Ramucirumab

TKI + VEGF Inhibition RELAY Trial - Results

Will This Strategy Apply to Osimertinib? Osimertinib + VEGF inhibition

TKI + Chemotherapy Gefitinib vs Gefitinib + Chemotherapy

TKI + Chemotherapy Results

Will This Strategy Apply to Osimertinib? Osimertinib + Chemotherapy

Will This Strategy Apply to Osimertinib Will This Strategy Apply to Osimertinib? Osimertinib + Chemotherapy (cont)

Mechanism of Resistance to EGFR TKI MET Amplification

Subsequent Line Metastatic Treatment Options in EGFRm NSCLC

EGFR/cMET Inhibition Bispecific Antibody: JNJ-372

Targeting HER3 ADC: U3-1402

Treating Patients With Exon 20 Insertions EGFR/HER2 inhibition: TAK 788

Leptomeningeal Disease

Diagnostics and Real World Experience

2L Therapy in Patients With EGFRm NSCLC

Chemo IO Combinations Keynote 189: PD-(L)1 Inhibitor and Osimertinib

Immunotherapy in ≥2L EGFRm NSCLC

IMpower150 Atezolizumab + Bevacizumab and Chemotherapy

Earlier Treatment Options in EGFRm NSCLC

EGFR TKIs as Adjuvant Therapy

Does a Longer Duration of Therapy Provide Greater Benefits?

Upcoming Trials to Watch

Complementary Therapy

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)